Jasper Therapeutics, Inc.·4

Jun 13, 8:54 PM ET

Mahal Jeetinder Singh 4

4 · Jasper Therapeutics, Inc. · Filed Jun 13, 2023

Insider Transaction Report

Form 4
Period: 2023-06-13
Mahal Jeetinder Singh
DirectorCEO and President
Transactions
  • Exercise/Conversion

    Voting Common Stock

    2023-06-13$0.71/sh+9,000$6,390296,223 total
  • Sale

    Voting Common Stock

    2023-06-13$1.66/sh9,000$14,915287,223 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2023-06-13+9,000173,713 total
    Exercise: $0.71Exp: 2030-05-31Voting Common Stock (9,000 underlying)
Footnotes (3)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.69, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
  • [F3]25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares have vested and shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary